Why is Fulgent repurchasing shares while reporting net losses?

Companies often conduct buybacks during loss periods to manage capital structure and support EPS metrics in the long term. Fulgent ended Q2 2026 with $551.5 million in cash and investments, providing ample liquidity for the program. The company's board may view the stock as undervalued or use repurchases as part of capital allocation strategy independent of near-term profitability.

What was the average price paid for shares repurchased in Q2 2026?

Fulgent repurchased 1.5 million shares for $23.8 million in Q2 2026, reflecting an average price of $15.87 per share. Year-to-date, the company has bought back 4.1 million shares for $63.9 million, or an average of approximately $15.58 per share.

How much authorization remains under Fulgent's buyback program?

The filing does not disclose the original authorization amount, total remaining authorization, or the date the program was authorized. The company only reports execution activity and states that future repurchases depend on stock price, market conditions, and board discretion.

Does Fulgent plan to continue repurchasing shares in the second half of 2026?

The company's forward guidance for 2026 assumes no further repurchases under the stock repurchase program for the remainder of the year. However, the company notes that timing and amounts of future repurchases may change based on market conditions and other factors the board deems relevant.

How did the buyback affect Fulgent's share count and EPS?

Year-to-date repurchase of 4.1 million shares reduced weighted-average basic shares outstanding to 29.4 million for the first half of 2026, versus 30.7 million in the prior-year period—a reduction of roughly 4.2 percent. This mechanical share reduction helps mitigate EPS dilution despite operating losses.

FLGT 8-K Filed 2026-07-30 Execution disclosure

Fulgent Genetics repurchased 1.5M shares at $15.87 in Q2 2026

Biotech company bought back stock totaling $23.8M in second quarter; 4.1M shares retired year-to-date

Shares repurchased1.5M

Avg price paid$15.87

MechanismNot specified

What the filing says

Fulgent Genetics, Inc. (NASDAQ: FLGT) executed its ongoing stock repurchase program in the second quarter of 2026, purchasing approximately 1.5 million shares for a total cash outlay of $23.8 million. This represents an average price of $15.87 per share based on the disclosed quarterly execution figures.

Year-to-date through June 30, 2026, the company has repurchased 4.1 million shares for $63.9 million in cash outlay, according to the earnings guidance. The company notes that the timing and amount of any future repurchases will depend on market conditions, stock price, general economic conditions, and factors the board deems relevant. The company's outlook assumes no further repurchases under the program for the remainder of 2026.

The repurchase activity reduced weighted-average basic shares outstanding from 30.5 million in the same quarter a year prior to 28.0 million in Q2 2026. The company ended June 30, 2026 with $551.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities, providing substantial capacity for potential future buyback activity.

Executed on stock repurchase program; purchased approximately 1.5 million shares in the second quarter of 2026 totaling $23.8 million in cash — Fulgent Genetics, Inc. 8-K filing · View on SEC EDGAR →

What this means

This filing reports execution of an existing buyback program rather than authorization of a new one. The company repurchased 4.1 million shares year-to-date for $63.9 million, reducing share count by roughly 13.5 percent compared to the prior-year period. While the filing discloses quarterly and year-to-date execution details, it does not specify the original authorization amount, remaining authorization, or buyback mechanism (Rule 10b-18, ASR, or other). The repurchase activity supports earnings-per-share metrics, though the company reported GAAP and non-GAAP losses in both Q2 and the year-to-date period. The company's forward guidance assumes no additional repurchases for the remainder of 2026.

Frequently asked questions

Why is Fulgent repurchasing shares while reporting net losses?: Companies often conduct buybacks during loss periods to manage capital structure and support EPS metrics in the long term. Fulgent ended Q2 2026 with $551.5 million in cash and investments, providing ample liquidity for the program. The company's board may view the stock as undervalued or use repurchases as part of capital allocation strategy independent of near-term profitability.
What was the average price paid for shares repurchased in Q2 2026?: Fulgent repurchased 1.5 million shares for $23.8 million in Q2 2026, reflecting an average price of $15.87 per share. Year-to-date, the company has bought back 4.1 million shares for $63.9 million, or an average of approximately $15.58 per share.
How much authorization remains under Fulgent's buyback program?: The filing does not disclose the original authorization amount, total remaining authorization, or the date the program was authorized. The company only reports execution activity and states that future repurchases depend on stock price, market conditions, and board discretion.
Does Fulgent plan to continue repurchasing shares in the second half of 2026?: The company's forward guidance for 2026 assumes no further repurchases under the stock repurchase program for the remainder of the year. However, the company notes that timing and amounts of future repurchases may change based on market conditions and other factors the board deems relevant.
How did the buyback affect Fulgent's share count and EPS?: Year-to-date repurchase of 4.1 million shares reduced weighted-average basic shares outstanding to 29.4 million for the first half of 2026, versus 30.7 million in the prior-year period—a reduction of roughly 4.2 percent. This mechanical share reduction helps mitigate EPS dilution despite operating losses.

execution mid-cap biotech share-reduction ongoing-program

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.